PT-141 Research Hub · Evidence Overview

PT-141 (bremelanotide) research evidence: what has actually been studied?

A review of melanocortin-receptor-agonist research, including controlled human trials, safety signals, and the limits of extrapolating from an approved drug product.

JD BioWorks Research LibraryPublished: July 15, 2026Last reviewed: July 15, 2026Editorial review: JD BioWorks Research Library

Evidence at a glance

Human evidenceSubstantial relative to many compounds in this library: randomized phase 2 and phase 3 studies evaluated a defined bremelanotide drug product in specific populations.

Preclinical evidenceMelanocortin-receptor pharmacology and animal studies informed development and mechanism research.

Evidence gapApproved-product evidence does not establish equivalence of independently supplied research material or outcomes outside studied populations and protocols.

ScopePT-141 is commonly used as a research name for bremelanotide. Identity, formulation, route, and product quality remain central to evidence relevance.

Interpretation note: Findings must stay tied to the exact molecule, formulation, model, population, and endpoint studied. A biological signal is not, by itself, proof of safety or effectiveness.

Overview

Bremelanotide is a melanocortin-receptor agonist developed from research on alpha-melanocyte-stimulating-hormone analogues. Human development included intranasal early studies and later subcutaneous studies. A specific finished drug product has FDA approval for a defined indication; that approval and evidence do not transfer to other materials bearing the name.

Research background

The RECONNECT program consisted of two phase 3 randomized, double-blind, placebo-controlled trials in premenopausal women with acquired, generalized hypoactive sexual desire disorder. Earlier dose-finding studies and ambulatory blood-pressure research helped characterize efficacy measures and transient cardiovascular effects.

Findings by research area

Research area	What has been reported	What it does not establish
Phase 3 trials	Two randomized studies enrolled 1,267 participants and evaluated desire and distress endpoints.	Results in other populations or with another product.
Safety signals	Nausea, flushing, headache, and transient blood-pressure changes were reported.	General safety without contraindication and label context.
Early studies	Intranasal and subcutaneous protocols explored PK/PD and dose selection.	Equivalence across routes or formulations.

Human evidence

Human data

The two RECONNECT trials randomized participants to 24 weeks of bremelanotide or placebo and reported statistically significant differences in prespecified desire and distress measures. Nausea, flushing, and headache were more common with active treatment. A separate randomized ambulatory-monitoring study detected small, transient increases in blood pressure with reductions in heart rate. These data are meaningful for the studied drug product and participants, but they do not validate an uncharacterized research preparation.

Preclinical evidence

Animal data

Preclinical melanocortin research examined central pathways and behavioral endpoints. Such models helped define targets but do not reproduce human subjective outcomes or safety constraints.

Laboratory evidence

In-vitro and analytical context

Receptor assays characterize melanocortin-receptor agonism and selectivity. They do not capture central nervous system distribution, cardiovascular responses, or patient-reported outcomes.

Research limitations

Evidence applies to a defined finished drug product and protocol.
Patient-reported endpoints require careful interpretation and validated instruments.
Cardiovascular and tolerability findings remain important context.
A research material cannot be presumed equivalent to the approved product.

Future research

Future research may refine receptor selectivity, identify predictors of response and adverse events, and expand comparative data, while maintaining exact product identity and appropriate regulatory context.

Primary references

Article record

Research question: What does the published evidence on PT-141 show across human, animal, and laboratory research?
Evidence cutoff: July 15, 2026
Article status: Published educational research summary; not independently peer reviewed
Author: JD BioWorks Research Library
Editorial review: JD BioWorks Research Library
Planned review cycle: At least annually, or sooner if material evidence or regulatory information changes

This article summarizes published research for educational and laboratory-information purposes. It is not medical advice, does not provide instructions for personal use, and does not establish that any material is safe or effective for human or veterinary use.

CONTINUE YOUR REVIEW

Next steps for qualified researchers

Use the public documentation resources below, then continue to Research Product Access when you are ready to review the gated catalog.

Search Certificates of Analysis Match available analytical records to the named product, quantity, and lot. Explore Research Guides Review HPLC, LC-MS, purity, identity, storage, and traceability guidance. Get Research Product Access Complete the Research Use Acknowledgment to create an account and receive automatic product access.

For qualified laboratory, analytical, educational, or institutional research only. Not for human or veterinary use.